Further development of the ImmuPHAGE™ model has been the focus of Amjad’s work during his time at ImmuONE. This model is composed of alveolar macrophage-like cells which are assembled in vitro in well plates and closely mimic the form and function of their human counterparts found within the alveoli of the deep lung.
At ImmuONE, we believe in fostering the growth and development of young talents in the field of biotechnology. Our commitment to nurturing bright minds extends beyond cutting-edge research; it’s about shaping the future of healthcare by empowering the leaders of tomorrow. We offer secondary school students valuable experiences through initiatives like the Nuffield Research Placements, which allow young people to find out what it’s like to work in a real biotech company and engage in a meaningful scientific project. Today, we’d like to introduce two of our promising students, Beverley Twum and Riqza Shad, who recently embarked on a two-week placement journey with us. Nilab Hydare, pre-clinical scientist at ImmuONE, skillfully led the project and served as a supportive mentor and supervisor to the students. Their guidance and expertise were instrumental in the success of this endeavor. They’ve agreed to share their insights and experiences, offering a glimpse into what they’ve learned at ImmuONE.
More than half of aerosol medicines under development are terminated due to safety concerns. ImmuONE’s high content imaging or cell painting assays are proven to accurately predict the safety of inhaled compounds by quantifying mechanism-linked morphological and biochemical characteristics within cells, contributing to faster, more informed decision making in the early stages of inhaled drug development.
Despite the increasing power of non-animal approaches, the move towards their inclusion in pharmaceutical safety testing is slow, largely due to a lack of familiarity among regulators.
Lung macrophages play a significant role in the chronic inflammation associated with cystic fibrosis